Please assess the completion status of the following clinical trial:

Trial Title: A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥18 years diagnosed with Chronic Phase Philadelphia chromosome positive (CP Ph+) CML who have failed to achieve CCyR after 3-18 months of therapy with imatinib 400 mg~* Treatment initiation with imatinib 400 mg within 6 months of initial CML diagnosis~* Able to tolerate chronic administration of imatinib at the highest dose (400-600 mg) the subject has received in the past~* Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2~* Adequate hepatic and renal function~Exclusion Criteria:~* Eligible and willing to undergo immediate autologous/allogeneic stem cell transplant~* Previous diagnosis of accelerated/blast crisis CML~* Subjects with clonal evolution in Ph+ cells observed in ≥2 metaphases~* Previous documentation of T315I mutation~* Uncontrolled or significant cardiovascular disease~* Serious uncontrolled medical disorder/active infection~* History of significant bleeding disorder unrelated to CML~* Intolerance to imatinib ≥400 mg~* Concurrent malignancies other than CML

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): 50-180 mg once daily (QD)
- B (Type: ACTIVE_COMPARATOR): 200-800 mg QD

Based on this trial design, predict the completion outcome and termination type (if applicable).